Senti Biosciences Holdings, Inc. (SNTI) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Senti Biosciences Holdings, Inc. (SNTI) closed at USD 0.24 on 2026-10-14, a change of -89.2 % over the past year, with a market capitalization of USD 8.14M.

Senti Biosciences Holdings, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Senti Biosciences Holdings, Inc. key figures

Previous close

USD 0.24 (2026-10-14)

1-year change

-89.2 %

Market cap

USD 8.14M

Enterprise value

USD 21.76M

P/E ratio (trailing)

-0.15

P/E ratio (forward)

-0.28

EPS (trailing)

-1.76

EPS (forward)

-0.95

PEG ratio

n/a

Price to book

-2.40

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

0.47

Employees

39

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Senti Biosciences Holdings, Inc.

Senti Biosciences Holdings, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The company's lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications with unmet need. It offers SENTI-202, a logic gated off-the-shelf CAR-NK cell therapy for the treatment of blood cancers and relapsed/refractory hematological malignancies, including acute myeloid leukemia. In addition, the company develops the tumor-associated antigen and protective antigen paired discovery platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. Further, its pipeline includes preclinical programs, which comprise a solid tumor cell therapy program; and partnered programs related to cell therapies for regenerative medicines. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd. The company was formerly known as Senti Biosciences, Inc. and changed its name to Senti Biosciences Holdings, Inc. in April 2026. The company was incorporated in 2016 and is headquartered in South San Francisco, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Senti Biosciences Holdings, Inc. and compare it with other stocks.